A Phase 3 interventional study of Fimasartan 120mg and Atorvastatin 40mg in Essential Hypertension, Dyslipidemia, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-05.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing fimasartan in Essential Hypertension — none open to participants now, none under way, none of them phase 3. fimasartan · Essential Hypertension.
Among the 21 studies testing fimasartan in Essential Hypertension, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 9 in phase 3, and was the 18th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →None of the 21 studies testing fimasartan in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is close to the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 92 across the 21 interventional studies. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 2 most frequent:
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd: 8 open now, 8 under way, 1 of them phase 3. Of 36 finished, 3 (8%) have results posted.
Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2018, is one of 11 in phase 3, and was the 21st registered.
Boryung Pharmaceutical Co., Ltd’s Essential Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing fimasartan in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boryung Pharmaceutical Co., Ltd’s 44 in Essential Hypertension:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
Drug: Fimasartan 120mg · Drug: Atorvastatin 40mg
Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
Drug: Fimasartan 120mg · Drug: Placebo for Atorvastatin 40mg
Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
Drug: Atorvastatin 40mg · Drug: Placebo for Fimasartan 120mg
Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
SiSBP
The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 2(Atorvastatin 40mg)
Time frame: 8weeks from Baseline Visit
LDL-C
The change in LDL-C from baseline in the test group at Week 8 compared to the active comparator group 1(fimasartan 120 mg)
Time frame: 8weeks from Baseline Visit
SiSBP
The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 1(Fimasartan 120mg)
Time frame: 8weeks from Baseline Visit
LDL-C
The change in LDL-C from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 2(Atorvastatin 40mg)
Time frame: 8weeks from Baseline Visit
Ran from Jan 2018 to primary completion in Apr 2019, 15 months.
Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 15 months is close to that.
Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fimasartan · Atorvastatin
Boryung Pharmaceutical Co., Ltd →